3 Lucrative Stocks We Choose to Overlook

Profitable Companies Aren’t Always Built to Last

Just because a business is currently generating profits doesn’t guarantee its future success. Some companies depend on outdated strategies or temporary advantages, making their long-term prospects uncertain.

While profitability is important, it’s not the only factor to consider. At StockStory, our goal is to help you spot companies with genuine long-term potential. Below, we highlight three profitable businesses that fall short of our standards, along with some more promising alternatives.

Newmark (NMRK)

12-Month GAAP Operating Margin: 5.8%

Newmark (NASDAQ:NMRK), established in 1929, is a provider of commercial real estate services. Its offerings include leasing advice, global corporate solutions, investment sales and capital markets, property and facilities management, valuation, and consulting.

Reasons We Avoid NMRK:

• Over the past five years, annual revenue growth has averaged just 11.6%, lagging behind other consumer discretionary companies.
• Its free cash flow margin has remained low at 1.7% for the last two years, limiting its ability to reinvest or reward shareholders.
• On a positive note, the company’s return on capital has been improving, indicating better investment decisions by management.

Newmark shares trade at $14.24, reflecting a forward P/E of 7.6.

D.R. Horton (DHI)

12-Month GAAP Operating Margin: 12.3%

D.R. Horton (NYSE:DHI) is among the largest homebuilders in the United States, constructing a wide range of new homes across various regions.

Why We’re Cautious About DHI:

• The company’s order backlog has declined by an average of 13.7% over the last two years, suggesting future revenue growth may fall short.
• Earnings per share have dropped by 11% annually over the past two years, a worrying trend since long-term stock performance often tracks EPS.
• Returns on capital have been slipping, indicating that its most profitable business areas may be losing steam.

D.R. Horton is currently priced at $147.18 per share, with a forward P/E of 13.8.

Repligen (RGEN)

12-Month GAAP Operating Margin: 7.5%

Since 2012, Repligen (NASDAQ:RGEN) has expanded its bioprocessing portfolio through more than 13 acquisitions. The company specializes in developing and manufacturing advanced technologies that enhance the efficiency and adaptability of biologic drug production.

What Makes RGEN a Risky Bet?

• With annual revenues of $738.3 million, Repligen is at a scale disadvantage compared to larger industry players.
• Operating expenses have grown as a share of revenue over the past five years, with adjusted operating margin dropping by 18.3 percentage points.
• Returns on capital have declined from an already weak position, suggesting that both past and current investments are not delivering the expected benefits.

Repligen’s stock is priced at $132.38, equating to a forward P/E of 61.1.

Top Stocks for Any Market Environment

Don’t Miss: The Top 5 Momentum Stocks
The ideal time to invest in a standout company is when the market starts to recognize its potential. These businesses aren’t just fundamentally strong—something significant is happening right now, combining solid performance with short-term momentum.

See which stocks our AI-driven platform is highlighting this week.

Our 2020 picks included well-known names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Tecnoglass, which delivered a 1,754% five-year return.